Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 861-874

  Cardinal, H ^a   Dieude M ^a   Brassard, N ^a   Qi, S ^a   Patey, N ^b   Soulez, M ^a   Beillevaire, D ^a   Echeverry, F ^c   Daniel, C ^c   Durocher, Y ^d   Madore, F ^e   Hebert M J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c INRS INSTITUT ARMAND FRAPPIER   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Acute rejection; antibodies; apoptosis; kidney transplantation

Indexed keywords

ANTIBODY; CALCINEURIN INHIBITOR; CD4 ANTIGEN; IMMUNOGLOBULIN G; PERLECAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY;

ADULT; ANIMALS; ANTIGENS; AORTA; APOPTOSIS; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; GRAFT REJECTION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; VASCULAR DISEASES;

EID: 84875693197     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12168     Document Type: Article

References (30)

1. Mueller A, Schnuelle P, Waldherr R, van der Woude FJ,. Impact of the Banff '97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation. Transplantation 2000; 69: 1123-1127. (Pubitemid 30217596)
2. Wilkinson A,. The 'First Quarter': The first Three Months After Transplant. In:, Danovitch G, ed. Handbook of Kidney Transplantation. Philadelphia: Lippincott Williams and Wilkins, 2010: pp. 198-216.
3. Terasaki PI, Ozawa M, Castro R,. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415. (Pubitemid 46096334)
4. Dragun D., Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019-1025.
5. Zhang Q, Reed EF,. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010; 22: 682-688.
6. Zou Y, Stastny P, Susal C, Dohler B, Opelz G,. Antibodies against MICA antigens and kidney transplant rejection. N Engl J Med 2007; 357: 1293-1300. (Pubitemid 47481451)
7. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569. (Pubitemid 40204669)
8. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90: 1473-1477.
9. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML,. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007; 170: 1415-1427. (Pubitemid 47339348)
10. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886-892. (Pubitemid 32417348)
11. Carter V, Shenton BK, Jaques B, et al. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654-657. (Pubitemid 40590660)
12. Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5: 383-393. (Pubitemid 40179526)
13. Ishii Y, Sawada T, Kubota K, Fuchinoue S, Teraoka S, Shimizu A,. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 2005; 67: 321-332. (Pubitemid 40019255)
14. Liptak P, Kemeny E, Morvay Z, et al. Peritubular capillary damage in acute humoral rejection: An ultrastructural study on human renal allografts. Am J Transplant 2005; 5: 2870-2876. (Pubitemid 43923946)
15. Cailhier JF, Sirois I, Laplante P, et al. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem 2008; 283: 27220-27229.
16. Soulez M, Pilon EA, Dieude M, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res 110: 94-104.
17. O'Riordan E, Mendelev N, Patschan D, et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl 2008; 2: 1025-1035.
18. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
19. Hopkins KA,. The Basic Lymphocyte Microcytotoxicity Test. In:, Phelan DL, Mickelson EM, Noreen HS, Shroyer TW, Cluff DM, Nikaen A, eds. ASHI Laboratory Manual (3rd ed.). Lenexa, KS: American Society for Histocompatibility and Immunogenetics, 1993: I.B.1.1-1.13.
20. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
21. Soulez M, Sirois I, Brassard N, et al. Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK 1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells 28: 810-820.
22. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584. (Pubitemid 28536132)
23. Koulack J, McAlister VC, Giacomantonio CA, Bitter-Suermann H, MacDonald AS, Lee TD,. Development of a mouse aortic transplant model of chronic rejection. Microsurgery 1995; 16: 110-113.
24. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738-741. (Pubitemid 32588032)
25. Cornell LD, Smith RN, Colvin RB,. Kidney transplantation: Mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189-220. (Pubitemid 351488280)
26. Sis B, Einecke G, Chang J, et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 2010; 10: 421-430.
27. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of 4 d staining. Am J Transplant 2009; 9: 2312-2323.
28. Joosten SA, van Dixhoorn MG, Borrias MC, et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310. (Pubitemid 34411634)
29. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008; 85: 1557-1563.
30. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-8